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SUMMARY 
 
The potency and efficacy of an avian influenza (AI) H5N2 inactivated vaccine that was developed at Veterinary Research Institute, 
Ipoh was tested. The percentage sequence identity of the HA gene of the H5N2 vaccine virus to the challenge virus 
[A/chicken/Malaysia/5858/04 (H5N1)] was 88.2% by nucleotide and 90% by amino acid sequences similarities, respectively. As for the 
HAI segment, the nucleotide sequence similarities were 88.3 % and by amino acid sequence 87.7%.For potency testing, the heterologous 
killed H5N2 AI vaccine, formulated as an oil emulsion was administered only once subcutaneously in twenty five two-week old 
commercial broiler chickens.  The HI antibodies were not detectable at week 1 post vaccination.  The HI GMT attained was 30, 63, 200, 
54 and 32 by week 2, 3, 4, 5, and 6 post vaccinations. Efficacy study was conducted on ten SPF chickens at week 3 post vaccination.  
60% of the birds (6/10) with HI titres ≥ 64 - 128 survived the challenged. H5N1 challenge virus was reisolated from all the birds with HI 
titre ≤ 32 that died, and each of the birds that survived with HI titres of 64 and 128, from the oropharynx and cloaca at day 3 post 
challenge.  This vaccine protected 60% of chickens against mortality and did not prevent shedding after challenged with a HPAI H5N1 
virus.  
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INTRODUCTION 
 
 Since the outbreaks of highly pathogenic avian 
influenza (HPAI) H5N1 in poultry in 2000 to 2004, various 
countries have adopted several strategies to control or 
eradicate the disease. Some have chosen stringent measures 
such as killing and destruction of infected poultry. 
However, as these methods proved to be expensive and 
biosecurity measures and culling cannot be implemented to 
successfully control or eradicate the disease for some 
countries, an alternative method, is therefore, vaccination. 
Vaccination is also one of the tools recommended by 
international health organisations in controlling AI (OIE). 
For this reasons only two types of vaccines have been 
currently approved, (i) heterologous low pathogenic 
inactivated vaccines and (ii) recombinant vaccines (Swayne 
et al., 2000). Since the emergence of H5N1 in Asia, several 
heterologous inactivated vaccines have been developed and 
tested against H5 and H7 influenza viruses in poultry and 
the use of heterologous inactivated H5N2 vaccines had been 
reported in chickens in Hong Kong (2002 - 2006), Pakistan 
(2006), India (2006), Russia (2005), Egypt (2006), in ducks, 
geese and chickens in China (2004) and Vietnam (2005) to 
name a few (Swayne et al., 2001; Swayne et al., 2006; 
Swayne 2009). Although these vaccines can protect poultry 
from clinical disease, sterile immunity is not achieved under 
field conditions, allowing for undetected virus spread and 
evolution under immune cover (Fuchs et al., 2009). 
However, controlling highly pathogenic H5N1 using  
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inactivated highly pathogenic H5N1 vaccines are not 
permissible for fear that residual viruses that are not fully 
inactivated can cause outbreaks. Despite this, in 2003, 
Indonesia, however, started using an autologous inactivated 
H5N1 vaccine to control the rapid spread of H5N1 in its 
poultry population (Swayne, 2009). However, they showed 
that the inactivated homologous H5N1 vaccine being 
completely protective than the H5N2 virus vaccines against 
H5N1 challenged. In using inactivated heterologous 
vaccines, where the virus strain used to make the vaccine is 
of the same H subtype as the challenging field virus the 
clinical protection and the reduction or viral shedding are 
ensured by the homologous H group (Capua and Marangon, 
2003). Similar HA subtype or high percentage homology 
(90 - 96%) between the vaccine strain and the circulating 
strain are critical factors for the efficacy of the vaccine.  
However, other factors such as antigen quantity and content 
and the adjuvant used for the efficacy of the inactivated 
vaccines are also important (Swayne et al., 1999; Wood et 
al., 1985). The ability of the heterologous vaccine to 
provide protection against mortality and morbidity, reduce 
cloacal and oropharyngeal shedding and ability to prevent 
viral spread to other vaccinated or susceptible birds have 
been considered as important factors for protective efficacy 
of the vaccine. The aim of the study is to determine the 
potency and efficacy of the inactivated H5N2 vaccine 
developed, and the ability of the vaccine to invoke sterile 
immunity as depicted by shedding of challenge virus, after 
challenged with a highly pathogenic Malaysian strain of 
H5N1 virus.  
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MATERIALS AND METHODS  
 
Viruses 
 
The vaccine virus A/duck/Malaysia/8443/04 H5N2 was 
isolated from the cloacal swab of a duck in a routine 
surveillance study in the country. During isolation of the 
virus in 9 - 11 day-old SPF embryonated eggs, the HA 
activity was detected as early as the first passage. However, 
it took 4 passages before the virus kill the SPF embryonated 
eggs. The virus was non-pathogenic as determined by the 
intravenous pathogenicity index (IVPI) by the standard 
procedure (Council Directive 92/40/EEC (1992) Off. J. Eur. 
Communities L167, 1 - 16). The sequence of the HA 
cleavage site is TIGECPKYVKSDRLVLAKGLRNVPQ----
RETRGLF. 
The challenge virus strain used was 
A/chicken/Malaysia/5858/04 H5N1. This virus was isolated 
from chickens during an outbreak in Malaysia in 2004. The 
virus had an intravenous pathogenicity index (IVPI) of 3.0, 
where 4 weeks old chickens inoculated with this virus died 
within 24 hr (determined by AAHL, Geelong, Australia, the 
OIE Reference Centre for Avian Influenza). The presence 
of multiple basic amino-acids at the HA cleavage site 
sequence of 
TIGECPKYVKSNRLVLATGLRNSPQRERRRKKRGLF 
indicated the high pathogenicity of the virus. The lethal 
dose of the virus was determined to be 10
5
EID50/0.1ml 
where it causes 100% mortality of SPF chickens within 48 
hr post-infection. All laboratory and animal experiments 
using the highly pathogenic H5N1 virus was performed in a 
BSL-3 facility of the Veterinary Research Institute, Ipoh, 
Malaysia. 
 
Sequencing of the Haemagglutinin gene 
 
PCR was carried out to amplify the full length HA gene 
of the H5N1 challenge virus A/chicken/Malaysia/5858/04 
H5N1 and the A/duck/Malaysia/8443/04 H5N2, using HA 
specific primers as previously described (Hoffmann et al., 
2001). The products were cloned into TOPO PCR vector 
and sequenced. Sequences were assembled and edited using 
Staden Package, Pairwise sequence alignments and the 
nucleotide and amino acid sequence were compared using 
the Bio-Edit 7 and Genetyx-Mac programmes. 
 
Preparation of the H5N2 Vaccine 
 
The master seed and working viruses of the duck 
isolate were prepared in SPF eggs. A preliminary batch of 
vaccine virus was produced by inoculating a batch of 500 
SPF eggs with 10
3.4 
EID50/0.1 ml (This dose was found to 
give the highest virus titre at day 3 post inoculation). 
Vaccine virus infected eggs were incubated for 3 days.  The 
undiluted allantoic fluid containing virus was inactivated for 
18 hr with B-propiolactone at 0.01 %v/v and adjuvanted 
with 10%Montanide™ gel. The pre-activation infectivity 
titre and the HA titre of the vaccine virus were 10
7.3
 
EID50/0.1 ml and 128 HAU respectively.  
For determining the potency of the H5N2 inactivated 
vaccine, twenty five three-day old commercial broilers 
which were not vaccinated with any poultry vaccines were 
reared until they reached the age of two weeks-old. The 
birds were wing-banded and reared in a non-infectious 
animal housing unit. 
 
Vaccination response-experiment 
 
At two weeks old, the birds were immunized with the 
H5N2 vaccine. A dosage of 200µl was injected 
subcutaneously (SQ) per bird, and the serology of all the 
immunized birds were evaluated every week for a period of 
6 weeks.   
 
HI assay 
 
The detection of antibodies after vaccination was 
studied by the HI assay performed according to the WHO 
manual on Animal Influenza diagnosis and Surveillance 
(WHO/CDS/CSR/NCS/2002.5). Serum samples were 
diluted 2 fold, with the initial serum dilution at 1:2. Titres > 
3 log2(8) are considered positive. The serological response 
was evaluated for all birds before and after vaccination. The 
HI test was performed in V-bottom 96 well microtiter plates 
with 8 HAU/50µl of homologous inactivatedH5N1 antigen 
per well.  
 
Challenging vaccinated birds with H5N1 virus 
 
In another experiment, ten two-week old SPF chickens 
(raised at SPF chicken facility of Veterinary Research 
Institute, Ipoh, Malaysia) were vaccinated with 200µl of the 
H5N2 vaccine via the SQ route. At 3 weeks post 
vaccination (based on 100% seroconversion from earlier 
potency study), the birds were challenged with 200µl 
containing 10
5.3
EID50/bird of the H5N1 virus via the 
intranasal route. Challenging of the chickens with HPAI 
H5N1 virus, was conducted in a negative pressure isolator 
cabinet ventilated with HEPA-filtered air in a NATA-
certified biosafety level-3 facility of Veterinary Research 
Institute, Ipoh. Water and feed were provided at libitum. 
Five SPF birds that had not been vaccinated with the H5N2 
vaccine were also challenged with the same dose of virus.  
Clinical signs were monitored daily for one week post-
challenged. Cloacal and oropharyngeal swabs of each of the 
chickens were sampled at 3 days post challenge for H5N1 
virus re-isolation. Virus isolation was performed in 9 - 11 
days old SPF embryonated eggs using standard procedures 
(OIE, 2012). The presence of H5N1 challenge virus was 
detected using the HA test and confirmed using specific 
H5N1 haemagglutination-inhibition (HI) serological test. 
Three passages were undertaken and HA test performed at 
each passage before the samples were considered negative.  
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RESULTS  
 
HA gene sequence  
 
Compared to the challenge virus, the percentage 
sequence identity of the HA gene of the vaccine H5N2 and 
challenge virus H5N1 was 88.2% by nucleotide sequence 
(Figure 1) and 90% by amino acid sequence. As for the 
comparison of the HAI segment, the nucleotide sequence 
similarities were 88.3 % and by amino acid sequence was 
87.7% similarities. 
 
Vaccination response 
 
Table 1 and Figure 1, showed the HI GMT and the 
percentage of birds attaining positive HI titres at various 
weeks after a single vaccination dose with the H5N2 
vaccine at two weeks old. By week 1 post vaccination (pv), 
HI antibodies were not detectable in any of the 25 
vaccinated birds. By week 2 pv, 60% of the birds were 
positive (HI ≥ 8) for HI antibodies. By week 3pv, 100% of 
the birds seroconverted with positive HI titres; however, the 
titres were not high, where only seven birds had HI titres of 
64 and 128. By week 4 pv, the percentage of birds with 
positive titre reduced to 96%, however, achieved the highest 
GMT of 200 where 18/25 birds (32%) attained high HI 
antibody titres of 64-512; and by week 6 pv, the antibodies 
waned off to a GMT of 32 with 72% of the birds having 
positive titre. However, the probable percentage of 
protection against mortality, based on a protective titre of ≥ 
40 (Kumar et al., 2007), if birds were challenged with a 
pathogenic H5N1 strain would be 28%, 72%, 4% and 4% at 
week 3, 4, 5 and 6 post vaccination respectively (Figure 1). 
 
Figure 1: Pairwise sequence alignment of the H5N2 and H5N1 HA gene showing homology in their sequence 
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Table 1: Relationship of the potency, HI Geometric Mean Titre (GMT) and probable percentage protection afforded by 
the H5N2 vaccine on 25 commercial birds.  Chicks were vaccinated at two weeks old and each bird was inoculated SQ 
with 200µl vaccine (pre-activation titre: 107.3EID50/0.1ml) 
 
Challenged response and shedding 
 
Only ten birds were used for the challenge and 
shedding studies as there was limited space in the BSL-
3 cabinet for ease of handling the chickens. As was 
observed in the potency study, the rise of humoral HI 
antibodies were slow, i.e. it took three weeks post 
vaccination for all birds to seroconvert. Challenge was 
therefore done at week 3 pv, to ensure that all birds have 
antibody titres by then. The birds had pre challenged HI 
titres ranging from 8 – 128 i.e two birds with HI titre of 
8, two birds with HI titre of 32; four birds  with HI titre 
of 64 and two birds with HI titre of 128 (Figure 2). All  
four birds with HI titre ≤ 32 died during challenged. The 
birds died within 3 - 4 days post challenged. The six 
birds with HI titre ≥ 64 survived challenged with no 
clinical signs observed. Shedding was evaluated at only 
one time i.e. at 3 days post-challenged. Challenge H5N1 
virus was excreted in the oropharynx and cloaca when 
examined at 3 days post challenged in 7/10 birds (70%),  
 
i.e from four birds that died at 3 - 4 days post 
challenged, in one bird with HI titre of 64 and one bird 
with HI titre of 128. Birds showed signs of depression, 
ruffled feathers and loss of appetite before death. 
 
DISCUSSION 
 
The Government of Malaysia does not adopt 
the policy of routine vaccination of poultry against 
avian influenza.  However, in a worst case scenario, the 
government recognizes the potential of vaccination as a 
complementary measure in the control and eradication 
of HPAI, or at least for the vaccination of expensive or 
rare exotic birds. In view of this, a pilot batch of vaccine 
was prepared using a low pathogenic 
A/Duck/Malaysia/8443/04 (H5N2) virus.  In our study, 
even at a high pre-activation titre of H5N2 virus of 
10
7.3
EID50/0.1 ml, and adjuvanted with 10% montanide 
gel (a potent adjuvant), the HI titres invoked with a 
single vaccination of this vaccine is moderately low 
Week post 
vaccination 
No of 
birds 
HI 
titre 
GMT a/b (Percent) positive 
HI titre :HI ≥ 8 
Probable percentage of protection based on a 
protective titer HI value ≥ 40 (Kumar et al. 2007) 
0 (before vaccination) 25 <2 0 0/25 (0%) 0% 
1 25 <2 0 0/25 (0%) 0% 
2 5 
5 
5 
7 
3 
<2 
4 
8 
16 
32 
30 15/25 (60%) 0% 
3 4 
14 
5 
2 
16 
32 
64 
128 
63 25/25 (100%) 7/25 (28%) 
4 1 
2 
2 
2 
10 
6 
1 
1 
4 
8 
16 
32 
64 
128 
256 
512 
200 24/25 (96%) 18/25 (72%) 
5 2 
1 
2 
13 
6 
1 
<2 
2 
8 
16 
32 
128 
54 22/25 (88%) 1/25 (4%) 
6 4 
1 
2 
12 
5 
1 
<2 
2 
4 
8 
16 
64 
32 18/25 (72%) 1/25 (4%) 
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with the highest HI titre achieved was 512 in only one 
bird. It was only after three weeks post vaccination that 
100% seroconversion was observed. 
The HI antibody response could not be 
detected at 1 week post vaccination, however the GMT 
achieved its peak of 200 by week 4 pv but the antibodies 
waned off quickly by week 6 pv. This low-moderately 
low potency of the vaccine had also been shown by 
Kumaret al. (2007), in chickens vaccinated with a 
reverse genetic H5N3 isolate where the HA gene was 
derived from A/chicken/Vietnam H5N1. The chickens 
achieved suboptimal antibody response of HI < 40. He 
also showed that chickens with serologic responses of  >  
40 were protected against challenge with the H5N1 
virus.  He also showed that, at this protective titre, the 
virus could still be reisolated from one out of the 62 
birds tested.  In our potency study, using Kumar’s value 
of HI > 40 as the protective titre, at week 3 and 4 post 
challenged, the probable protection afforded would only 
be 28% and 72% respectively. However, in our 
challenged study, using ten SPF chickens, 60% 
protection was afforded when chickens were challenged 
at week 3 post vaccination. We were also able to 
reisolate the challenge H5N1 virus in 7/10 birds. In 
conclusion, the H5N2 inactivated vaccine invoked only 
sub-optimal humoral HI antibody titres, not enough to 
protect at least 80% of the birds against challenge, 
although the HA protein share  90% amino acid  
homology with  the challenge H5N1  virus.  According 
to Swayne et al., 1999, the degree of protection of 
inactivated vaccines is not strictly correlated to the 
degree of homology between the HA gene or protein of 
the vaccine and challenge strains, therefore the vaccine 
can still be improved to achieve a higher degree of 
clinical protection and a better reduction of shedding i.e. 
by increasing the antigen mass of the vaccine. Due to 
space constrains of the BSL-3 facility, this is only a 
preliminary and small study, and therefore there were 
insufficient numbers of birds at all the various HI titres 
to make statistical inferences of protection associated 
with titres. 
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